News Post

Exclusive: Wipro GE-backed GenWorks valuation touches Rs 550 Cr

Entrackr · 1m

Healthcare firm GenWorks has raised Rs 41 crore (around $5 million) in a funding round led by Evolvence Fund. Somerset Indus Healthcare Fund and key individuals from the Zawawi Group also joined the round. The board at GenWorks Health has passed a special resolution to issue 5,12,500 CCPS at an issue price of Rs 800 each to raise the above sum, its regulatory filing accessed from the Registrar of Companies shows. Evolvence Fund and Somerset Indus Healthcare Fund have injected Rs 26 crore and Rs 8.2 crore, respectively, while Kasiraman Swaminathan and Ramesh Kumar Sivaraman (Group CEO and Finance Manager of Zawawi Group) collectively invested Rs 8.2 crore. According to the startup data intelligence platform TheKredible, the Bengaluru-based company has been valued at around Rs 540-550 crore or $65 million (post-allotment). Following the fresh investment, Evolvence Fund has acquired a 1.51% stake whereas Somerset Indus Healthcare and both the key personnel of Zawawi Group hold 4.54% and 1.52%, respectively. Started as a Wipro GE invested entity, Genworks has raised over $33 million to date, including its $17 million investment round led by Wipro GE and Morgan Stanely in May 2022. Wipro Ge is a joint venture between the Indian IT major and American multinational GE Healthcare. The firm also bagged $4 million from BlackSoil in May 2023. Founded by S GaneshPrasad, GenWorks offers medical devices for Cardiology, ENT, IVD, newborn care, radiology and respiratory diagnosis, among others. As per its website, it has touched over 200 million people in India since its inception, and 6 million lives every year. The ten-year-old company has been growing at a brisk pace in the past few fiscal years. With Rs 447 crore in operating collection during FY23, it registered 20% year-on-year growth over FY22. Meanwhile, its losses also spiked 46% to Rs 44 crore in the same period. GenWorks is yet to report financial numbers for the last fiscal year (FY24).